medigraphic.com
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

2013, Number 6

<< Back Next >>

Rev Invest Clin 2013; 65 (6)

Genotype-phenotype correlation in a sample of Mexican patients with cystic fibrosis

Yokoyama E, Lezana JL, Vigueras-Villaseñor RM, Rojas-Castañeda J, Saldaña-Álvarez Y, Orozco L, Chávez-Saldaña M

Language: Spanish
References: 39
Page: 491-499
PDF size: 167.61 Kb.


ABSTRACT

Introduction. Cystic fibrosis is a lethal autosomal recessive disease, commonly seen in Caucasian population. The World Health Organization (WHO) estimated that in Mexico, the incidence is approximately 1 per 8,500 live births. Defects in CFTR (cystic fibrosis transmembrane conductance regulator) protein are responsible for alterations in the transport of chloride in the apical membrane of exocrine epithelial cells. This results to a lot of variability in the clinical manifestations, which range from a very serious disease that compromises the life of the patient, to only primary infertility due to absence of CBAVD. The study of the CFTR gene, responsible for this entity, has led to understand the correlation between the molecular defects in this gene and the clinical expression of the patients. Most reports show that only pancreatic function in CF patients directly correlated with genotype and not with other clinical features such as lung disease. Objective. In this work we analyzed the genotype-phenotype correlation in a cohort of Mexican patients with CF. Material and methods. We included 230 patients with CF, stratified based on the genotype and pancreatic disease. Both ratings were correlated with clinical parameters as in sweat chloride levels, lung disease, pancreatic insufficiency or sufficiency (IP and SP) and colonization by Pseudomonas aeruginosa (P. aeruginosa). Results and Discussion. Our data suggest a strong correlation between the severity of mutations and pancreatic function. Related to this, significant differences were observed in sweat chloride levels, lung disease, colonization by P. aeruginosa, and the age of onset of symptoms, and diagnosis among patients with IP and SP (p ‹ 0.001). The close correlation between IP, both with mutations that eliminate the function of CFTR gene, as with the presence of more serious clinical picture, suggests that IP could be used as an indicator of the severity of CF patients especially in those without characterized mutations yet.


REFERENCES

  1. Cutting GR. Cystic fibrosis. In: Rimoin DL, Connor MJ, Pyeritz RE (eds.). Principles and practice of medical genetics. 5th Ed. London: Churchill-Livingston: Emery and Rimon’s; 2007, p. 1561-606.

  2. The molecular genetic epidemiology of cystic fibrosis. WHO/ HGN/CF/WG/04.02

  3. Cystic Fibrosis Genetic Analysis Consortium. Available from: http//www.genet.sickkids.on.ca

  4. Rommens JM, Iannuzzi MC, Kerem B, Drumm ML, Melmer G, Dean M, Rozmahel R, et al. Identification of the cystic fibrosis gene: chromosome walking and jumping. Science 1989; 245: 1059-65.

  5. Culling B, Ogle R. Genetic counselling issues in cystic fibrosis. Paediatr Respir Rev 2010; 11(2): 75-9.

  6. Groman JD, Meyer ME, Wilmott RW, Zeitlin TL, Cutting GR. Variant cystic fibrosis phenotypes in the absence of CFTR. N Engl J Med 2002; 347: 401-07.

  7. Accurso FJ. Update in cystic fibrosis 2007. Am J Respir Crit Care Med 2008; 177(10): 1058-61.

  8. Goetzinger KR, Cahill AG. An update on cystic fibrosis screening. Clin Lab Med 2010; 30(3): 533-43.

  9. Kerem E, Kerem B. Genotype-Phenotype correlation in cystic fibrosis. Pediat Pulmonol 1996; 22: 387-95.

  10. Kerem B, Corey M, Kerem BS, Rommens J, Markiewicz D. The relation between genotype and phenotype in cystic fibrosis analysis of the most common mutation (delta F508). N Engl J Med 1990; 323: 1517-22.

  11. Durno C, Corey M, Zielenski J, Tullis E, Tsui LC, Durie P. Genotype and phenotype correlation in patients with cystic fibrosis and pancreatitis. Gastroenterology 2002; 123: 1857-64.

  12. Augarten A, Ben Tov A, Madgar I, Barak A, Akons H, Laufer J, Efrati O, et al. The changing face of the exocrine pancreas in cystic fibrosis: the correlation between pancreatic status, pancreatitis and cystic fibrosis genotype. Eur J Gastroenterol Hepatol 2008; 20(3): 164-8.

  13. Ooi CY, Dorfman R, Cipolli M, Gonska T, Castellani C, Keenan K, Freedman SD, et al. Type of CFTR mutation determines risk of pancreatitis in patients with cystic fibrosis. Gastroenterology 2011; 140(1): 153-61.

  14. Ooi CY, Durie PR. Cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations in pancreatitis. J Cyst Fibros 2012; 11(5): 355-62.

  15. Chávez-Saldaña M, Yokoyama E, Lezana JL, Carnevale A, Vigueras RM, López M, Orozco L. CFTR allelic heterogeneity in mexican patients with cystic fibrosis: implications for molecular screening. Rev Invest Clin 2010; 62(6): 546-52.

  16. Corey M, Edwards L, Levison H, Knowles M. Longitudinal analysis of pulmonary function decline in patients with cystic fibrosis. J Pediatr 1997; 131(6): 809-14.

  17. Brasfield D, Hicks G, Soong S, Tiller R. The Chest Roentgenogram in Cystic Fibrosis: A New Scoring System. Pediatrics 1979; 63(1): 24-9.

  18. Lezana JL. Fibrosis quística: guías clínicas para el diagnóstico y tratamiento: Enfermedad digestiva. Intersistemas Editores 2008; 103: 57-65.

  19. Duguépéroux I, De Braekeleer M. Genotype-Phenotype relationship for five CFTR mutations frequently identified in western France. J Cyst Fibros 2004; 3: 259-63.

  20. Braun AT, Farrell PM, Frerec C, Audrezet MP, Laxova A, Li Z, Kosorok MR, et al. Cystic Fibrosis mutations and genotypepulmonary phenotype analysis. J Cyst Fibros 2006; 5: 33-41.

  21. Shastri SS, Kabra M, Kabra SK, Pandey RM, Menon PSN. Caracterisation of mutations and genotype-phenotype correlation in cystic fibrosis: Experience from India. J Cyst Fibros 2008; 7: 110-5.

  22. Makukh H, Krenková P, Tyrkus M, Bober L, Hancarová M, Hnteyko O, Macek M. A high frequency of the Cystic Fibrosis 2184insA mutation in Western Ukraine: Genotype-phenotype correlation, relevance for newborn screening and genetic testing. J Cyst Fibros 2010; 8: 371-5.

  23. Salvatore D, Buzzetti R, Baldo E, Forneris MP, Lucidi V, Manunza D, Marinelli I, et al. An overview of international literature from cystic fibrosis registries. Part 3. Disease incidence, genotype/phenotype correlation, microbiology, pregnancy, clinical complications, lung transplantation, and miscellanea. J Cyst FIbros 2011; 10: 71-85.

  24. Geborek A, Hjelte L. Association between genotype and pulmonary phenotype in cystic fibrosis patients with severe mutations. J Cyst Fibros 2011; 10: 187-92.

  25. Poulou M, Fylaktou I, Fotoulaki M, Kanavakis E, Tzetis M. Cistic fibrosis genetic counseling difficulties due to the identification of novel mutations in the CFTR gene. J Cyst Fibros 2012; 11: 344-8.

  26. Salvatore F, Scudiero O, Castaldo G. Genotype-phenotype correlation in cystic fibrosis: The role of modifier genes. Am J Med Genet 2002; 111: 88-95.

  27. Castellani C, Cuppens H, Macek M Jr., Cassiman JJ, Kerem E, Durie P, Tullis E, et al. Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. J Cyst Fibros 2008; 7(3): 179-96.

  28. Orozco L, Chávez M, Saldaña Y, Velázquez R, Carnevale A, González-Del Angel A, Jiménez S. Cystic fibrosis: molecular update and clinical implications. Rev Invest Clin 2006; 58(2): 139-53.

  29. Rowntree R, Harris A. The phenotypic consequences of CFTR mutations. Ann Hum Genet 2003; 67: 471-85.

  30. Zielenski J. Genotype and phenotype in cystic fibrosis. Respiration 2000; 67(2): 117-33.

  31. Thauvin-Robinet C, Munch A, Huet F, Génin E, Bellis G, Gautier E, et al. The very low penetrance of cystic fibrosis for the R117H mutation: a reappraisal for genetic counselling and newborn screening. J Med Genet 2009; 46: 752-8.

  32. de Nooijer RA, Nobel JM, Arets HG, Bot AG, van Berkhout FT, de Rijke YB, de Jonge HR, et al. Assessment of CFTR function in homozygous R117H-7T subjects. J Cyst Fibros 2011; 10(5): 326-32.

  33. Saldaña-Alvarez Y, Jiménez-Morales S, Echevarría-Sánchez M, Jiménez-Ruíz JL, García-Cavazos R, Velázquez-Cruz R, Carnevale A, et al. Molecular screening of the CFTR gene in Mexican patients with congenital absence of the vas deferens. Genet Test Mol Biomarkers 2012; 16(4): 292-6.

  34. Monaghan KG, Highsmith WE, Amos J, Pratt VM, Roa B, Friez M, Pike-Buchanan LL, et al. Genotype-phenotype correlation and frequency of the 3199del6 cystic fibrosis mutation among I148T carriers: results from a collaborative study. Genet Med 2004; 6(5): 421-5.

  35. Ruchon AF, Ryan SR, Fetni R, Rozen R, Scott P. Frequency and phenotypic consequences of the 3199del6 CFTR mutation in French Canadians. Genet Med 2005; 7(3): 210-1.

  36. Claustres M, Laussel M, Desgeorges M, Demaille J. Identification of a 6 bp deletion (3195del6) in exon 17a of the cystic fibrosis (CFTR) gene. Hum Mol Genet 1994; 3(2): 371.

  37. Drumm ML, Ziady AG, Davis PB. Genetic variation and clinical heterogeneity in cystic fibrosis. Annu Rev Pathol 2012; 7: 267-82.

  38. Megiorni F, Cialfi S, Dominici C, Quattrucci S, Pizzuti A. Synergistic post-transcriptional regulation of the Cystic Fibrosis Transmembrane conductance Regulator (CFTR) by miR-101 and miR-494 specific binding. PLoS One 2011; 6(10): e26601.

  39. López-Corella E, Ridaura-Saenz C, López-Cervantes G. Cystic fibrosis in mexican children. A report of 32 cases in 3260 consecutives pediatric autopsies. Patología 1980; 18: 167-81.




2020     |     www.medigraphic.com